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The purpose of this study was to develop an eﬃcient way to synthesize
99mTc-O-[3-(1,4,8,11-tetraazabicyclohexadecane)-propyl]-
tyrosine (
99mTc-N4-Tyrosine), a novel amino acid-based radiotracer, and evaluate its potential in breast cancer gamma imaging.
Precursor N4-Tyrosine was synthesized using a 5-step procedure, and its total synthesis yield was 38%. It was successfully labeled
with
99mTc with high radiochemical purity (>95%). Cellular uptake of
99mTc-N4-Tyrosine was much higher than that of
99mTc-
N4 and the clinical gold standard 18F-2-deoxy-2-ﬂuoro-glucose (18F-FDG) in rat breast tumor cells in vitro. Tissue uptake and
dosimetryestimationinnormalratsrevealedthat
99mTc-N4-Tyrosinecouldbesafelyadministeredtohumans.Evaluationinbreast
tumor-bearing rats showed that although
99mTc-N4-Tyrosine appeared to be inferior to 18F-FDG in distinguishing breast tumor
tissue from chemical-induced inﬂammatory tissue, it had high tumor-to-muscle uptake ratios and could detect breast tumors
clearly by planar scintigraphic imaging.
99mTc-N4-Tyrosine could thus be a useful radiotracer for use in breast tumor diagnostic
imaging.
1.Introduction
18F-2-deoxy-2-ﬂuoro-glucose(18F-FDG),an 18F-labeledglu-
cose analog, is a gold standard for positron emission
tomography (PET) in cancer diagnosis. However, 18F-FDG-
PET has several limitations that can result in false positive or
negative diagnoses, and its ability to predict tumor response
to chemotherapy or radionuclide therapy is poor [1]. For
instance, 18F-FDG cannot distinguish tumor tissue from
inﬂammatory or normal brain tissues because each type of
tissuehashighglucoseconsumption.Therefore,radiolabeled
amino acids have been developed as an alternative to 18F-
FDG in diagnostic imaging of cancer. Their use in tumor
detection is based on an increased uptake of amino acids in
tumorcells,whichisassumedtoreﬂectenhancedaminoacid
transport, metabolism, and protein synthesis [2].
Among all radiolabeled amino acids, aromatic ones such
as tyrosine and its derivatives are more suitable for use
in cancer diagnostic imaging given their readily alterable
chemistry and favorable biological characteristics. To date,
tyrosine and its α-methyl-substituted analog α-methyl tyro-
sine (AMT) have been successfully labeled with 11C, 18F,
and 124/125If o rP E Ti m a g i n g ,a sw e l la s123/131I for single-
photon emission computed tomography (SPECT) imaging,
respectively [2–7]. Most of these radiolabeled tyrosine
analogs show promise in preclinical and clinical research in
diagnostic tumor imaging, especially for brain tumors. They
have also been successfully applied to imaging breast cancer,
whichisthemostcommonmalignancyamongwomeninthe
world. For instance, 11C-labeled tyrosine appears to be better
than 18F-FDG for breast cancer imaging because of its lower
uptake in noncancerous ﬁbrocystic disease [8].
However, most existing radiolabeled tyrosine derivatives
require an on-site cyclotron to produce the radioisotope,
which is inconvenient and costly. In addition to that, the
radioisotopes have either a too short (e.g., 20 minutes
for 11C) or too long (e.g., 57.4 days for 125I) half-life,
making them impractical for clinical use. Furthermore,2 Journal of Biomedicine and Biotechnology
iodine-labeled compounds are not stable in vivo because
of deiodination. So far, 18F has the most appropriate half-
life (110 minutes); however, the radiosynthesis yield of 18F-
labeled radiotracers is relatively low, apparently because of
the electrophilic ﬂuorination and tedious puriﬁcation of
18F. Therefore, a radiotracer with simpler chemistry and an
aﬀordable isotope that can be used clinically in most major
medical facilities is needed.
Technetium-99m (99mTc) is an ideal radioisotope for
diagnostic imaging studies because of its favorable physical
characteristics. It emits a 140keV gamma ray in 89%
abundance, which is commonly used in gamma and SPECT
imaging. The half-life of 99mTc is 6.02 hours, allowing serial
images and, thus, overcoming a drawback of 18F[ 9]. Unlike
most cyclotron-produced radionuclides, which use covalent
chemistry for labeling, 99mTc requires a chelator to conjugate
the radioisotope with the target ligand. The combinations of
nitrogen, oxygen, and sulfur appear to be stable chelators
for 99mTc [10–12]. In fact, this chelator could allow the
same target ligand to be labeled with several diﬀerent
radioisotopes, such as gallium-68, indium-111, or rhenium-
188, for future diagnostic and therapeutic applications.
Here, we report the synthesis of 99mTc-labeled tyrosine
using 1,4,8,11-tetra-azacyclotetradecane (N4) cyclam as a
chelator and evaluate its potential in gamma imaging using
in vitro and in vivo breast tumor models.
2.MaterialsandMethods
All chemicals of analytical grade and solvents of high-
performance liquid chromatography (HPLC) grade were
obtained from Sigma-Aldrich (St. Louis, MO, USA). Nuclear
magnetic resonance (NMR) was performed on a Bruker 300-
MHz spectrometer (Bruker BioSpin Corporation, Billerica,
MA, USA), and mass spectra were performed on a Waters
Q-TOF Ultima mass spectrometer (Waters, Milford, MA,
USA) at the chemistry core facility at The University of Texas
MD Anderson Cancer Center (Houston, TX, USA). Sodium
pertechnetate(Na99mTcO4)wasobtainedfroma 99Mo/99mTc
generator (Mallinckrodt, Hazelwood, MO, USA). 18F-FDG
was obtained from the Department of Nuclear Medicine at
MD Anderson.
2.1. Synthesis of Precursor N4-Tyrosine
2.1.1. N-t-Butoxycarbonyl-O-[3-Br-propyl]-L-tyrosine Methyl
Ester(Compound1). N-t-Butoxycarbonyl-L-tyrosinemethyl
ester (25.00g; 0.085mol) was dissolved in acetone (300mL).
1,3-Dibromopropane (17.3mL; 0.169mol) and K2CO3
(58.00g; 0.420mol) were added under a nitrogen atmo-
sphere. The reaction mixture was reﬂuxed at 80◦C overnight.
After the mixture was cooled and ﬁltered, the solvent
was removed under reduced pressure and the residue was
dissolved in chloroform. The residue was washed with water
and dried with anhydrous MgSO4. The product was puriﬁed
by column chromatography using a silica gel column eluted
withhexane:ethylacetate(2:1,v/v).Yield:33.30g(94.60%).
Ms (m/z) = 440.09 [M+Na]+.
2.1.2. N1,N4-Dioxylyl-1,4,8,11-tetraazabicyclotetradecane
(N1,N4-Cyclooxamide) (Compound 2). N4 cyclam (15.00g;
74.88mmol) was dissolved in 150mL of anhydrous ethanol,
and diethyl oxalate (10.94g; 74.88mmol) was added. The
reaction mixture was reﬂuxed for 18 hours at 75◦C. The
solvent was rotary evaporated, and the crude product was
dissolved in minimum quantity of ethanol and ﬁltered and
recrystallized in 400mL of acetone/ethanol to yield white
crystals of compound 2. Yield: 13.64g (71.62%). Ms (m/z)
255.19 [M]+.
2.1.3. N-t-Butoxycarbonyl-O-[3-(N1,N4-dioxylyl-1,4,8,11-tet-
raazabicyclotetradecane)-propyl]-tyrosine Methyl Ester (Com-
pound 3). Compound 2 (0.63g; 2.46mmol) was dissolved
in 20mL of anhydrous dimethylformamide; it was reacted
with a solution of compound 1 (1.06g; 2.46mmol) in 40mL
of dimethylformamide under a nitrogen atmosphere. The
mixture was reﬂuxed at 75◦C for 18 hours and then cooled
to room temperature. The reaction mixture was ﬁltered, and
the solvent was removed in vacuo. The crude compound was
puriﬁed via silica gel column using chloroform: methanol
solution (9:1, v/v). Yield: 0.65g (1.05mmol; 42.76%). Ms
(m/z) 591.31 [M]+.
2.1.4. O-[3-(N1,N4-Dioxylyl-1,4,8,11-tetraazabicyclotetrade-
cane)-propyl]-tyrosine Methyl Ester (Compound 4). To
deprotect N-t-butoxycarbonyl group, Compound 3 (0.60g;
1.00mmol) was dissolved in anhydrous dichloromethane
(15mL),and2.5mLoftriﬂuoroaceticacidwasaddedtoit.
The solution was stirred overnight at room temperature,
and the solvents were then removed in vacuo. The crude
compound was puriﬁed by chromatography over silica gel
(chloroform: methanol 9:1, v/v) giving an oﬀ-white solid.
Yield: 0.18g (90%). Ms (m/z) 490.31 [M]+.
2.1.5. O-[3-(1,4,8,11-Tetraazabicyclohexadecane)-propyl]-ty-
rosine (Compound 5, N4-Tyrosine). Compound 4 (0.25g;
0.50mmol) was dissolved in 5mL of water, and 2.5mL of
10N NaOH was added to it. The solution was stirred and
reﬂuxed overnight at 90◦C, and the solvent was evaporated
in vacuo. The crude compound was then dissolved in 5mL of
water, and the pH of the solution was neutralized to pH 7 by
adding5MHCl.Theﬁnalsolutionwaslyophilizedovernight
toobtainwhitepowder,whichwasthendissolvedin25mLof
anhydrous methanol, ﬁltered, evaporated, and lyophilized to
obtain oﬀ-white powder. Yield: 0.19g (88.78%). = Ms (m/z)
422.31 [M]+.
2.2. Radiolabeling of N4-Tyrosine with 99mTc. N4-Tyrosine
(1mg) was dissolved in 0.2mL of sterile water, and tin (II)
chloride(0.1mL,1mg/mL)wasadded.Therequiredamount
of Na99mTcO4 was added to the N4-Tyrosine solution at the
room temperature. Radiochemical purity was determined by
radio-HPLC using an C-18 reverse column (Waters), eluted
with a 7:3 acetonitrile: water solution (v/v) at a ﬂow rate of
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2.3. Determination of the Partition Coeﬃcient. To determine
the lipophilicity, 20μLo f99mTc-N4-Tyrosine was added into
an equal volume mixture of 1-octanol and sterile water
in a centrifuge tube. The mixture was vortexed at room
temperature for 1 minute and then centrifuged at 5,000rpm
for 5 minutes to allow phase separation. From each phase,
0.1mL of the aliquot was taken out, and the radioactivity
wasmeasuredbygammacounter(CobraQuantum,Packard,
MN, USA). The measurement was repeated 3 times, and
care was taken to avoid cross-contamination between the
phases. The partition coeﬃcient value, expressed as log P,
was calculated using the following equation:
LogP = log

radioactivity in 1-octanol layer
radioactivity in sterile water layer

(1)
2.4.InVitroCellularUptake. Ratbreasttumorcellline13762
(American Type Culture Collection, Rockville, MD, USA)
was used for both in vitro studies and to create the animal
model for in vivo evaluation. All cells were maintained in
Dulbecco’s modiﬁed Eagle’s medium and nutrient mixture
F-12 Ham (DMEM/F12; GIBCO, Grand Island, NY) at 37◦C
in a humidiﬁed atmosphere containing 5% CO2.
For in vitro cellular uptake analysis, cells were plated
onto 6-well tissue culture plates (2 × 105 cells/well)
48 hours before adding the radiotracers and incubated
with 99mTc-N4-Tyrosine (0.05mg/well, 8μCi/well), 99mTc-
N4 (0.025mg/well, 8μCi/well), or 18F-FDG (8μCi/well) for
0–4 hours. After incubation, cells were washed with ice-
cold phosphate-buﬀered solution twice and detached using
a treatment of 0.5mL of trypsin for 5 minutes. Cells were
thencollected,andtheradioactivityofthecellswasmeasured
in triplicate with a gamma counter (Cobra Quantum).
Radioactivity was expressed as mean ± standard deviation
(SD) percent of cellular uptake (%Uptake).
2.5. Blood Clearance. All animal work was carried out in
the Small Animal Imaging Facility at MD Anderson under
a protocol approved by the Institutional Animal Care and
Use Committee. For blood clearance analysis, 3 normal
female Fischer 344 rats (150 ± 25g; Harlan Sprague-Dawley,
Indianapolis, IN, USA) were intravenously injected with
30μCi of 99mTc-N4-Tyrosine. Blood samples (n = 3/rat)
were drawn from each rat through the lateral tail vein by
microliter pipette (10μL) at several time points between 5
minutes and 24 hours after injection. The blood samples
were measured for radioactivity by gamma counter, and the
radioactivity was expressed as a percentage of the injected
dose per gram of blood (%ID/g).
2.6. Tissue Distribution. Tissue distribution studies of
99mTc-N4-TyrosinewereconductedusingnormalfemaleFis-
cher 344 rats (150 ± 25g, n = 9). The rats were divided into
3 groups, and each rat was injected intravenously with 25
± 0.5μCi of 99mTc-N4-Tyrosine. Each group was examined
at 1 of 3 time points (0.5, 2, or 4 hours after injection). At
each time point, the rats were killed, and the selected tissues
were excised, weighed, and measured for radioactivity by
gammacounter.Foreachsample,radioactivitywasexpressed
as mean percentage of the injected dose per gram of tissue
wet weight (%ID/g). Counts from a 1/10 diluted sample of
the original injection were used as a reference.
2.7. OLINDA/EXM Dosimetry Estimates. Rat absorbed dose
estimates for 99mTc-N4-Tyrosine were computed from
biodistributiondata.Individualorganandwhole-bodytime-
activity curves were ﬁtted to exponential functions using
OLINDA/EXM software (version 1.1; Vanderbilt University,
Nashville, TN, USA). These functions were then integrated
analytically to determine the area under the curve to yield
the residence time of 99mTc-N4-Tyrosine in each organ. It
was assumed that the injected activity of 99mTc-N4-Tyrosine
was uniformly distributed throughout the body immediately
following injection. Mass correction factors were used to
account for the diﬀerent ratios of organs to total body weight
and diﬀerent scaling of residence times between rats and
humans [13]. Residence times were then used to calculate
target organ absorbed radiation doses for a 70kg standard
man model using the OLINDA/EXM software.
2.8. Planar Scintigraphic Imaging in Breast Tumor-Bearing
Rats. Cells from the breast tumor cell line 13762, suspended
inphosphate-buﬀeredsolution(105 cells/0.1mLsolutionper
rat), were injected subcutaneously into the right calf muscle
offemaleFischer344rats(n = 9).Planarscintigraphicimag-
ing of 99mTc-N4-Tyrosine was performed 12–14 days after
inoculation when tumors reached approximately 1cm in
diameter. The breast tumor-bearing rats (n = 3/time point)
wereanesthetizedandinjectedintravenouslywith 99mTc-N4-
Tyrosine (0.3mg/rat, 300μCi/rat), and images were acquired
at 30, 120, and 240 minutes after administration of tracers.
Planar scintigraphic images were obtained using M-CAM
(Siemens Medical Solutions, Hoﬀman Estates, IL, USA)
equipped with a low-energy high-resolution collimator.
Computer-outlined regions of interest (ROIs in counts per
pixel) between tumor and muscle tissue were used to
calculate tumor-to-muscle (T/M) ratios. Percent of injected
dose (%ID) in the tumor was also calculated from the
reference standard, which was 1/10 of the original injection
activity of 99mTc-N4-Tyrosine.
2.9. Tumor and Inﬂammation Uptake Comparison. To inves-
tigate whether 99mTc-N4-Tyrosine can diﬀerentiate tumor
tissue from inﬂammatory tissue, a rat model bearing both
a mammary tumor and tissue with turpentine oil-induced
inﬂammation was created. Rat breast tumor cells (from
cell line 13762; 105 cells/0.1mL phosphate-buﬀered solution
per rat) were injected into the right calf muscles of 3
female Fischer 344 rats. After the tumors reached 1cm in
diameter, turpentine oil (0.1mL/rat) was injected into the
left calf muscles of the rats to induce inﬂammation. The
anesthetized rats were injected intravenously with 99mTc-
N4-Tyrosine 24 hours after the turpentine injection. Planar
scintigraphic images were acquired at 30, 120, and 240
minutes after the 99mTc-N4-Tyrosine injection, and ROIs
of the tumor, inﬂamed tissue, and muscle were used to4 Journal of Biomedicine and Biotechnology
calculate the tumor-to-muscle ratios (T/Ms), inﬂammation-
to-muscle ratios (I/Ms), and tumor-to-inﬂammation ratios
(T/Is), respectively. The same animal model was used to
evaluate 18F-FDG. Micro-PET imaging of 18F-FDG was
performed using an R4 micro-PET scanner (Concorde
Microsystems, Knoxville, TN, USA). Three breast tumor-
and inﬂammation-bearing rats were injected intravenously
with 18F-FDG (500μCi/rat), and dynamic PET scans with
a spatial resolution of 2.2mm were obtained at 30, 60,
and 90 minutes after 18F-FDG injection. PET images were
reconstructed by using the ordered subset expectation max-
imization (OSEM) algorithm. T/M, I/M, and T/I ratios were
calculated using the regional radioactivity concentrations
(μCi/cm3)thatwereestimated fromtheaveragepixels within
ROIs drawn around the tumor, inﬂamed tissue, or muscle on
transverse slices of the reconstructed image sets.
3. Results andDiscussion
As mentioned previously, radiolabeled amino acid analogues
have shown great potentials in cancer imaging by targeting
the increased amino acids uptake in tumor cells. In the
present study, we report the synthesis of 99mTc-labeled
tyrosine using (N4) cyclam as a chelator and evaluate its
potential in breast cancer diagnosis using the breast tumor
models in vitro and in vivo.
3.1. Chemistry and Radiochemistry. The total synthesis yield
of precursor N4-Tyrosine via our 5-step procedure was 38%.
ThesyntheticschemeisshowninFigure 1.Thestructureand
purityofN4-Tyrosinewereconﬁrmedby 1H-and 13C-NMR,
massspectra,andHPLC.The 1H-NMRresults(D2Oδ,ppm)
wereasfollows:7.18(d,2H,phenylring),6.95(d,2H,phenyl
ring), 4.073 (t, 2H, O-CH2), 3.43 (t, 1H, CHN), 2.28–3.00
(m, 2OH, OCH2 and NCH2-), 1.87–1.91(m, 2H, C-CH2-C),
and1.68–1.79(m,4H,C-CH2-C). 13C-NMRresults(D2Oδ,
ppm) were as follows: 162.88, 156.72, 130.76, 117.57, 115.25,
68.55, 57.29, 53.91, 51.56, 49.95, 49.17, 48.96, 48.24, 48.03,
46.80, 45.73, 45.35, 39.27, 24.90, 24.31, and 23.87. Because
the starting material, N-t-butoxycarbonyl-L-tyrosine methyl
ester, was commercially available, the synthetic yield of N4-
Tyrosine in our study was much higher (38%) than that of its
α-methyl derivative N4-AMT (14%), which was reported in
ap r e v i o u ss t u d y[ 14].
For the radiolabeling, the top and middle panels of
Figure 2 show the ultraviolet absorbance of 99mTc-N4-
Tyrosine at 210nm and 274nm, while the bottom panel
indicates the peak from NaI detector that only detects the
radioactivity. Since precursor N4-Tyrosine has a unique
ultraviolet absorbance at 274nm, we selected 274nm for
one of the ultraviolet detectors. On the other hand, the
210nm detector can detect almost every molecule; therefore,
we were able to detect any impurities in our compound.
The retention time of three detectors matched very well,
which indicated precursor N4-Tyrosine was labeled with
99mTc successfully with high radiochemical purity (>95%).
Because 99mTc-N4-Tyrosine is a kit product and labeled
without any further puriﬁcation, its radiochemical yield was
assumed to be identical to its radiochemical purity. For the
partition coeﬃcient value, the log P of 99mTc-N4-Tyrosine
was −2.83 ± 0.082, which was lower than that of its α-
methyl derivative 99mTc-N4-AMT (−2.02 ± 0.168). Since
the log P value is positively correlated with lipophilicity
of the compound, we found that the lipophilicity of the
tyrosine-based radiotracer could be increased by adding a
methyl group on its α-carbon.
3.2. In Vitro Cellular Uptake Evaluation. The cellular uptake
kinetics of 99mTc-N4-Tyrosine, 99mTc-N4, and 18F-FDG in
r a tb r e a s tt u m o rc e l l si ss h o w ni nFigure 3. The uptake
for 99mTc-N4-Tyrosine increased dramatically up to 240
minutes, but this was not true for the 99mTc-N4 chelator,
suggesting that 99mTc-N4-Tyrosine can enter tumor cells
speciﬁcally and accumulate rapidly. In addition, the mean
%Uptake of 99mTc-N4-Tyrosine was much higher than that
of 18F-FDG, which indicated that 99mTc-N4-Tyrosine had
better imaging potential than 18F-FDG in this in vitro breast
cancer model.
3.3.InVivoEvaluationinNormalFischer344Rats. Theblood
clearance curve for 99mTc-N4-Tyrosine in normal Fischer
344 rats is shown in Figure 4. The plasma half-life of the
distribution phase (t1/2α)w a s9 .31 ± 0.759 minutes, and
the plasma half-life of the elimination phase (t1/2β)w a s
90.14 ± 1.901 minutes, indicating that 99mTc-N4-Tyrosine
had relatively fast blood clearance in normal rats.
Tissue distribution of 99mTc-N4-Tyrosine in normal Fis-
cher 344 rats is shown in Table 1. Low thyroid and stomach
uptake of 99mTc-N4-Tyrosine was observed, suggesting that
99mTc-N4-Tyrosine has high stability in vivo.H i g hu p t a k e
was found in the kidneys, which was consistent with the
planar scintigraphic imaging ﬁndings in the breast tumor-
bearing rats (see Figure 5). This high kidney uptake may be a
resultofthelowlipophilicityof 99mTc-N4-Tyrosine,oritmay
be related to the biological characteristics of 99mTc-labeled
tyrosine because similar results were also observed in the
previously developed tyrosine-based radiotracers 99mTc-N4-
AMT, 99mTc-EC-AMT, and 99mTc-EC-Tyrosine [14, 15].
To estimate the maximum dose of 99mTc-N4-Tyrosine
that could be safely administered to humans, individ-
ual organ absorbed radiation doses were calculated using
OLINDA/EXM software. Estimates of the doses per unit
administered are shown in Table 2. The kidneys received
the highest absorbed dose (4.86E-02mSv/MBq or 1.80E-
01rem/mCi), which made it the dose-limiting organ. Other
organswithrelativelyhighabsorbedradiationdosesincluded
the heart wall, spleen, and liver. According to the US Food
and Drug Administration regulations, human exposure to
radiationfromtheuseof“radioactiveresearchdrugs”should
be limited to 3rem per single administration and 5rem per
year to the whole body, blood-forming organs (red marrow,
osteogenic cells, spleen), the lens of the eye, and gonads
(testes and uterus); the limit for other organs is 5rem per
single administration and 15rem annually. Total rem of
99mTc-N4-Tyrosine absorbed by each organ was below these
limits at the proposed injection of 15mCi per patient.Journal of Biomedicine and Biotechnology 5
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Table 1: In vivo tissue distribution of 99mTc-N4-Tyrosine in normal Fischer 344 rats (n = 3) at 30, 120, and 240 minutes after injection.
Organ 30 MIN 120 MIN 240 MIN
Blood 0.88 ±0.040 0.20 ±0.018 0.17 ±0.009
Heart 0.21 ±0.022 0.06 ±0.003 0.05 ±0.003
Lung 0.50 ±0.023 0.19 ±0.011 0.14 ±0.006
Thyroid 0.34 ±0.019 0.10 ±0.010 0.09 ±0.006
Pancreas 0.17 ±0.017 0.07 ±0.012 0.05 ±0.002
Liver 1.15 ±0.059 0.70 ±0.040 0.67 ±0.044
Spleen 0.94 ±0.089 0.76 ±0.032 0.63 ±0.051
Kidney 11.05 ±0.783 12.34 ±0.502 12.40 ±0.405
Stomach 0.20 ±0.018 0.08 ±0.003 0.06 ±0.002
Intestine 0.34 ±0.057 0.13 ±0.010 0.11 ±0.006
Muscle 0.07 ±0.007 0.03 ±0.002 0.02 ±0.001
Bone and joint 0.24 ±0.021 0.15 ±0.008 0.12 ±0.008
Brain 0.03 ±0.001 0.02 ±0.001 0.01 ±0.001
Each value indicates the percent of injected dose per gram of wet weight (%ID/g, n = 3/time point). Each data represents mean of three measurements with
standard deviation.
Table 2: Absorbed radiation dose estimates (dose per unit injected into a 70kg adult man) for 99mTc-N4-Tyrosine.
Target organ
Absorbed radiation dose estimates Human dose (15mCi)
mSv/MBq rem/mCi rem
Adrenals 4.65E −03 1.72E −02 2.58E −01
Brain 4.69E −04 1.74E −03 2.61E −02
Breasts 1.27E −03 4.72E −03 7.08E −02
Gallbladder wall 3.79E −03 1.40E −02 2.10E −01
Lower large intestine wall 1.62E −03 6.00E −03 9.00E −02
Small intestine 2.70E −03 1.00E −02 1.50E −01
Stomach wall 2.49E −03 9.21E −03 1.38E −01
Upper large intestine wall 2.44E −03 9.04E −03 1.36E −01
Heart wall 8.51E −03 3.15E −02 4.73E −01
Kidneys 4.86E −02 1.80E −01 2.70E +00
Liver 5.52E −03 2.04E −02 3.06E −01
Lungs 2.27E −03 8.41E −03 1.26E −01
Muscle 1.34E −03 4.96E −03 7.44E −02
Ovaries 1.76E −03 6.53E −03 9.80E −02
Pancreas 3.76E −03 1.39E −02 2.09E −01
Red marrow 1.91E −03 7.07E −03 1.06E −01
Osteogenic cells 5.21E −03 1.93E −02 2.90E −01
Skin 8.91E −04 3.30E −03 4.95E −02
Spleen 5.66E −03 2.09E −02 3.14E −01
Testes 7.91E −04 2.93E −03 4.40E −02
Thymus 2.29E −03 8.47E −03 1.27E −01
Thyroid 1.25E −03 4.61E −03 6.92E −02
Urinary bladder wall 1.39E −03 5.14E −03 7.71E −02
Uterus 1.77E −03 6.53E −03 9.80E −02
Total Body 1.98E −03 7.32E −03 1.10E −01
Eﬀective dose equivalent 5.71 E−03 2.11E −02 3.17E −01
Eﬀective dose 2.19 E−03 8.11E −03 1.22E −01Journal of Biomedicine and Biotechnology 7
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Figure 3: In vitro cellular uptake of 99mTc-N4-Tyrosine, 99mTc-N4,
and 18F-FDG in cells from rat breast tumor cell line 13762. Data are
expressed as mean percent of cellular uptake ± standard deviation
(%Uptake ± SD) measured at 15, 30, 60, 120, and 240 minutes after
coincubation with 99mTc-N4-Tyrosine.
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Figure 4: Blood clearance curve of 99mTc-N4-Tyrosine in normal
female Fischer 344 rats (n = 3). Mean radioactivity is expressed as
mean percentage of the injected dose per gram of blood ± standard
deviation (%ID/g ± SD).
3.4. In Vivo Evaluation in Breast Tumor-Bearing Rats. The
selected planar scintigraphic images of breast tumor-bearing
rats at 30, 120, and 240 minutes after 99mTc-N4-Tyrosine
injection are shown in Figure 5. The T/M ratios at 30, 120,
and 240 minutes were 5.12, 4.88, and 5.20, respectively.
Tumor %ID at these three time points were 1.82%, 1.87%,
and 1.71%, respectively. Tumors could be clearly detected by
99mTc-N4-Tyrosine at all time points.
30 min 120 min 240 min
T
T/M = 5.12 T/M = 4.88 T/M = 5.2
Tumor %ID: 1.82 Tumor %ID: 1.87 Tumor %ID: 1.71
Figure 5: The selected planar scintigraphic images of breast tumor-
bearing rats at 30, 120, and 240 minutes after 99mTc-N4-Tyrosine
injection (T indicates tumor; T/M, tumor-to-muscle ratio; tumor
%ID, percent of injected dose in the tumor).
Theselectedplanarscintigraphicimagesofbreasttumor-
and inﬂammation-bearing rats at 30, 120, and 240 minutes
after 99mTc-N4-Tyrosine injection, as well as micro-PET
images at 30, 60, and 90 minutes after 18F-FDG injection,
are shown in Figure 6.T h eT / Mr a t i oo f99mTc-N4-Tyrosine
was relatively higher than I/M ratio at each time point.
Although T/I ratios were greater than 1 at all time points
for both 99mTc-N4-Tyrosine and 18F-DFG, indicating that
the tumor had higher uptake than the inﬂammation site, the
T/I ratios for 99mTc-N4-Tyrosine were lower than those for
18F-FDG. This suggests that 99mTc-N4-Tyrosine was inferior
to 18F-FDG in diﬀerentiating tumor from inﬂammation
in this breast tumor-bearing rat model. However, we used
turpentine to induce inﬂammation chemically in this model.
It may be worth testing 99mTc-N4-Tyrosine in another
animal model using radiation to induce inﬂammation so
that the model better mimics patients undergoing radiation
therapy.
4. Conclusion
In summary, N4-Tyrosine was synthesized and labeled eﬃ-
ciently with 99mTc with high radiochemical purity. Although
it appears to inferior 18F-FDG in distinguishing breast tumor
tissue from chemical-induced inﬂammatory tissue, 99mTc-
N4-Tyrosine has high tumor-to-muscle uptake ratios and
can detect breast tumor tissue clearly by gamma camera.
By taking the advantage of chelator N4 cyclam, we could
label N4-Tyrosine with gallium-68 for PET imaging and,
furthermore, labeled with rhenium-188 for radionuclide
therapy for breast cancer treatment in future.
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Figure 6: The selected planar scintigraphic images of breast tumor- and inﬂammation-bearing rats at 30, 120, and 240 minutes after 99mTc-
N4-Tyrosine injection and micro-PET images at 30, 60, and 90 minutes after 18F-FDG injection (T indicates tumor; I, inﬂammation).
Tumor-to-muscle (T/M), inﬂammation-to-muscle (I/M), and tumor-to-inﬂammation (T/I) ratios are shown in the tables.
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